
Germany · Mechanical or industrial engineering startup
SWARM Biotactics is a German-American deep-tech company founded in 2024, specializing in bio-robotics.
Funding reportedLast round: Seed
SWARM Biotactics is a German-American deep-tech company founded in 2024, specializing in bio-robotics.
The company develops programmable living organisms, primarily Madagascar hissing cockroaches, equipped with miniaturized electronic backpacks. These "cyborg swarms" are designed to gather real-time data in challenging environments where traditional technology may struggle. Headquartered in Kassel, Germany, with a subsidiary in San Francisco, SWARM Biotactics has grown to over 40 engineers. The company has secured €13 million in funding from various investors. Its core product, the bio-robotic swarm system, features advanced hardware components, including neural stimulation for control and edge AI processors for decision-making. The proprietary SWARM OS platform coordinates the insects, enabling them to operate autonomously or under manual guidance. SWARM Biotactics serves mission-critical sectors such as defense, disaster response, industrial inspection, and environmental sensing. The company has established relationships with customers, including NATO members and Germany's Bundeswehr, providing innovative solutions for reconnaissance and data collection in high-risk areas.
Funding, as reported
What they build
Known for
data protectionbio-robotic systemslow signature sensorstransportation_logisticsdistributionmanufacturingfield deploymentneural interfaceselectrophysiologyeducationwireless rf technologiesinformation technology & servicesinterdisciplinary bio-roboticscluttered terrain accessbioroboticsinsect-based platforms
Built with from their website
DockerWordPress.orgAWS Trusted AdvisorFont AwesomeApacheGitHubViewport MetaEmail Encoder for WordpressElement UISignal
BabelFriendly Captcha.NETAWS LambdaPriority HintsGoogle Font APIMicrosoft ExchangeMySQL
Add your raise, your deck and your story, and put SWARM Biotactics in front of investors. Or tell us what we have wrong.